Deuterium enriched analogues of tadalafil as PDE5 inhibitors
The present invention relates to derivatives of tadalafil represented by the formula: or a salt thereof, wherein: X 1 and X 2 are simultaneously fluoro; or X 1 is deuterium and X 2 is selected from hydrogen or deuterium; each Y is independently selected from deuterium or hydrogen; the hydrogen attached to the indole nitrogen is optionally replaced by deuterium; and each carbon is independently optionally replaced by 13 C. These compounds are selective PDE5 inhibitors and possess advantageous biopharmaceutical and pharmacokinetic properties. The invention further provides compositions comprising these compounds and methods of treating diseases and conditions that are responsive to PDE5 inhibition, alone and in combination with additional agents.
1. An isolated compound of Formula II:
or a pharmaceutically acceptable salt thereof; wherein:
X 1 and X 2 are simultaneously fluoro;
each of Y 3 , Y 4 , Y 6 , Y 7 , Y 8a , Y 8b , Y 9a , Y 9b , Y 9c , Y 10 , Y 11a , Y 11b , Y 13 , Y 14 , Y 15 , and Y 16 is independently selected from deuterium or hydrogen;
the hydrogen attached to the indole nitrogen is optionally replaced by deuterium; and
each carbon is independently optionally replaced by 13 C.
2. The compound or salt according to claim 1 , having a formula:
wherein the hydrogen attached to the indole nitrogen is not replaced by deuterium and wherein no carbon atoms are replaced by 13 C.
3. The compound or salt according to claim 1 , wherein all hydrogen atoms not replaced by deuterium and all carbon atoms not replaced by 13 C are present at their natural isotopic abundance.
4. A pharmaceutical composition comprising an effective amount of a compound or salt according to claim 1 ; and a pharmaceutically acceptable carrier.